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ABSTRACT
Objective To investigate changes in quality of life 
(QoL), cognition and functional status according to 
arrhythmia recurrence after atrial fibrillation (AF) 
ablation.
Methods We compared QoL, cognition and functional 
status in patients with recurrent atrial tachycardia (AT)/
AF versus those without recurrent AT/AF in the AXAFA–
AFNET 5 clinical trial. We also sought to identify factors 
associated with improvement in QoL and functional 
status following AF ablation by overall change scores 
with and without analysis of covariance (ANCOVA).
Results Among 518 patients who underwent AF 
ablation, 154 (29.7%) experienced recurrent AT/AF at 3 
months. Patients with recurrent AT/AF had higher mean 
CHA2DS2- VASc scores (2.8 vs 2.3, p<0.001) and more 
persistent forms of AF (51 vs 39%, p=0.012). Median 
changes in the SF-12 physical (3 (25th, 75th: −1, 8) 
vs 1 (−5, 8), p=0.026) and mental scores (2 (−3, 9) vs 
0 (−4, 5), p=0.004), EQ- 5D (0 (0,2) vs 0 (−0.1, 0.1), 
p=0.027) and Karnofsky functional status scores (10 
(0, 10) vs 0 (0, 10), p=0.001) were more favourable in 
patients without recurrent AT/AF. In the overall cohort, 
the proportion with at least mild cognitive impairment 
(Montreal Cognitive Assessment <26) declined from 
30.3% (n=157) at baseline to 21.8% (n=113) at follow- 
up. ANCOVA identified greater improvement in Karnofsky 
functional status (p<0.001) but not SF-12 physical 
(p=0.238) or mental scores (p=0.065) in those without 
recurrent AT/AF compared with patients with recurrent 
AT/AF.
Conclusions Patients without recurrent AT/AF appear 
to experience greater improvement in functional status 
but similar QoL as those with recurrent AT/AF after AF 
ablation.
INTRODUCTION
Catheter ablation is increasingly employed treat-
ment option for rhythm control in patients with 
atrial fibrillation (AF).1 While some clinical trials 
have shown that catheter ablation can improve 
cardiovascular outcomes in certain patient groups, 
the primary indication for catheter ablation in 
current practice is to improve symptoms and 
quality of life (QoL).1–4 Interestingly, improvements 
in symptom burden and QoL have been observed 
even in patients with recurrent AF.5
Despite evidence that catheter ablation is more 
effective than antiarrhythmic drug therapy for 
the treatment of recurrent AF, catheter ablation is 
associated with infrequent but measurable peripro-
cedural risks, including stroke. Moreover, high- 
resolution diffusion weighted brain MRI identifies 
acute brain lesions without neurological symp-
toms in 10%–40% of patients undergoing catheter 
ablation.6 7 MRI- detected acute brain lesions may 
contribute to cognitive decline in patients who 
are treated with catheter ablation. These potential 
adverse effects of catheter ablation are concerning, 
especially in view of the mainly symptomatic bene-
fits for patients.8 9
In order to examine the impact of the results of 
catheter ablation on symptoms, QoL, and cogni-
tion, we compared these important outcomes 
in patients with and without recurrent AF in the 
AXAFA clinical trial.10
METHODS
The rationale and design of AXAFA–AFNET 5 
(Anticoagulation using the direct factor Xa inhibitor 
apixaban during Atrial Fibrillation catheter Abla-
tion: Comparison to vitamin K antagonist therapy) 
have been described previously.10 In brief, AXAFA- 
AFNET 5 was an investigator- initiated, prospec-
tive, parallel- group, randomised, open, blinded 
outcome assessment study comparing continuous 
apixaban therapy to vitamin K antagonist therapy 
during ablation. AXAFA- AFNET 5 was conducted 
in Europe and North America. The trial sponsor 
was AFNET, Münster, Germany ( www. kompe-
tenznetz- vorhofflimmern. de). AXAFA–AFNET 5 
was designed by the steering committee in coop-
eration with AFNET and conducted in accordance 
with the declaration of Helsinki and the Interna-
tional Conference on Harmonization Good Clinical 
Practice Guidelines. The protocol was approved by 
ethical review boards at all institutions. The Clin-
ical Research Institute (CRI, Munich, Germany) 
executed the study in cooperation with the steering 
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committee and the sponsor. Data collection and entry was 
performed using the MARVIN eCRF system.10 An independent 
steering committee and an independent data and safety moni-
toring board guided the trial. Patients were not involved in the 
design of the trial. All adverse events were adjudicated by an 
independent endpoint review committee blind to study group 
and INR values. The Duke Clinical Research Institute served as 
the statistical core and performed the statistical analyses for the 
trial. The authors vouch for the accuracy and completeness of 
the data and for the fidelity of the trial to the protocol. This 
manuscript was written by the authors.
Study population
AXAFA–AFNET 5 enrolled patients scheduled for a de novo/
first AF ablation with at least one established stroke risk factor 
(age >65 years, heart failure, hypertension, diabetes or prior 
stroke). For the purpose of this analysis, the study population 
included all patients from the AXAFA trial population who were 
randomised, underwent catheter ablation and had available 
baseline and follow- up QoL data.
Measures and outcomes
Several QoL and cognitive function measures were prospec-
tively collected in AXAFA at baseline and 3- month follow- up, 
including EQ- 5D, SF-12, modified European Heart Rhythm 
Association (mEHRA) classification, Karnofsky performance 
status, and Montreal Cognitive Assessment (MoCA) Test scores.
The EQ- 5D was developed by the EuroQol group and is a 
short, standardised measure of generic health. The EQ- 5D 
assesses five dimensions across three response levels: mobility, 
self- care, usual activities, pain/discomfort and anxiety/depres-
sion. For the purpose of this analysis, the summary index was 
used in which the score ranges from 0 to 1, where higher scores 
reflect better health status.
The SF-12 is an abbreviated 12- item generic health related 
QoL measure derived from the Short Form 36. The measure 
evaluates physical functioning, limitations due to physical health 
problems, bodily pain, energy/fatigue, social functioning, limita-
tions due to emotional problems, and psychological distress 
and well being. The SF-12 is reported as the physical compo-
nent summary (PCS) and mental component summary (MCS). 
Higher scores indicate better health status. Samsa and colleagues 
defined the minimal clinically important difference (MCID) for 
the PCS as 3 in a cardiovascular (CV) population11 and Clement 
and colleagues12 have calculated the MCID as 2.7 (in a non- CV 
population). MCID values for the MCS are more variable and 
have not been well- quantified in patients with cardiovascular 
disease. In patients with joint disease, the reported absolute 
MCID values range from 1.4 to 4.5.13
The mEHRA classification assesses symptoms and functional 
limitation due to AF. The score is ordinal where class 1 represents 
no symptoms, class 2a represents mild symptoms (not trouble-
some to patient), class 2b represents moderate symptoms (trou-
blesome to patient), class 3 represents severe symptoms (impacts 
normal daily activity) and class 4 represents disabling symptoms 
(normal daily activity is discontinued).14
The Karnofsky performance score is an instrument used to 
evaluate functional capacity. Originally developed in oncology, 
the score has been used in assessments of cardiovascular inter-
ventions.15 The Karnofsky score ranges from 100 to 0, where 
100 is ‘perfect’ health and 0 is death.
The MoCA evaluates global cognition by assessing short term 
memory, visuospatial abilities, executive function, attention, 
concentration and working memory, language and orientation to 
time and place. The MoCA has 30 test items and can be admin-
istered in approximately 10 min. It is scored between 0 and 30 
with higher values indicating better cognitive function. A score 
of 26 or higher indicates normal cognitive function.16
Changes in quality- of- life and cognitive function compared 
with baseline were prespecified secondary outcomes in AXAFA. 
As per study design, we also assessed freedom from atrial tachy-
cardia (AT) or AF postablation (referred to as AF hereafter) after 
a 3- month blanking period as per consensus definition.
Statistical analysis
Changes in QoL, cognitive function and functional status were 
assessed at 3 months compared with baseline using the EQ- 5D 
and SF-12 questionnaires, MoCA, and Karnofsky scale. Changes 
in QoL and cognitive function were evaluated separately by anal-
ysis of covariance (ANCOVA) models (SF-12 physical compo-
nent scores, SF-12 mental component scores, Karnofsky scores 
and MoCA). The ANCOVA model included the recurrent AT/
AF status as an indicator variable and adjustment for the baseline 
quality- of- life values. Multiple linear regression was conducted 
on changes in 3- month SF-12 scores (MCS and PCS) using clin-
ically important baseline measures. These measures included age 
(years); sex; weight (kg); body mass index (kg/m2); systolic and 
diastolic blood pressure (mm Hg); Cockcroft- Gault estimated 
creatinine clearance (mg/dL); New York Heart Association func-
tional classification; prior history of diabetes, stroke or tran-
sient ischaemic attack, vascular disease (coronary, peripheral, 
or carotid), mitral valve disease, aortic valve disease or chronic 
obstructive pulmonary disease; prior major bleeding; type of 
AF (paroxysmal versus persistent/long- standing persistent AF); 
modified EHRA (I, IIa, IIb, III, IV); MoCA; and rhythm at start 
of ablation (sinus rhythm, AF, atrial flutter, pacing, or other). 
A sensitivity analysis was conducting using multiple logistic 
regression assessing the difference in the proportion of patients 
showing a 2.5 point or more improvement in their MCS and 
PCS scores. Descriptive statistics for continuous and categor-
ical variables were summarised as means (SDs), median (25th, 
75th percentiles) and counts (percentages), respectively. Unad-
justed statistical comparisons between continuous variables were 
performed using the Wilcoxon rank- sum test or two- sample 
t- test depending on normality; comparisons between nominal 
variables were performed using the Pearson’s χ² test or Fisher’s 
exact test, depending on expected cell sizes (n<5). All analyses 
were two- sided and tested at the nominal 0.05 significance level, 
and no adjustment was made for multiple testing.
Statistical analyses were performed with SAS V.9.4 (SAS Insti-
tute, Cary, North Carolina, USA).
RESULTS
Baseline characteristics
Among 518 patients undergoing ablation with available QoL 
data (82% of all patients undergoing AF ablation), 154 (29.7%) 
experienced recurrent AT/AF at the end of follow- up (3 months). 
Patients with recurrent AT/AF had higher CHA2DS2- VASc scores 
(3 (25th, 75th: 2, 3) vs 2 (1,3), p<0.001), more frequently had 
heart failure (37.7% vs 29.1%, p=0.04), prior stroke or transient 
ischaemic attack (11.7% vs 6.0%, p=0.028), coronary artery 
disease (17.5% vs 10.7%, p=0.033) and prior major bleeding 
(5.2% vs 0.8%, p=0.004) compared with patients who had no 
recurrent AT/AF (table 1). In terms of medical therapy, patients 
with recurrent AT/AF were less likely to be on flecainide (13.6% 
vs 22.3%, p=0.024). Patients with recurrent AT/AF were less 
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Table 1 Baseline characteristics in those with and without recurrent AT/AF*
All patients Recurrent AT/AF No recurrent AT/AF
P valuen=518 n=154 n=364
Age, median (q1, q3) 64 (58 to 70), 65 (60 to 70), 64 (57 to 70), 0.076
Female 174 (33.6%) 61 (39.6%) 113 (31.0%) 0.059
Weight, median (q1, q3) 87 (76 to 98) 88 (77 to 101) 86 (76 to 97) 0.231
BMI, median (q1, q3) 28 (25 to 31) 29 (26 to 32) 28 (25 to 31) 0.184
CHA2DS2VASc score, median (q1, q3) 2 (2 to 3) 3 (2 to 3) 2 (1 to 3) <0.001
Hypertension, n (%) 468 (90.3%) 136 (88.3%) 332 (91.2%) 0.307
Systolic blood pressure, median (q1, q3) 140 (125 to 151) 139 (125 to 151) 140 (125 to 150) 0.990
Diastolic blood pressure, median (q1, q3) 83 (76 to 90) 85 (76 to 92) 81 (75 to 90) 0.145
COPD, n (%) 33 (6.4%) 8 (5.2%) 25 (6.9%) 0.476
Heart failure 164 (31.7%) 58 (37.7%) 106 (29.1%) 0.040
  NYHA I 48 (9.3%) 18 (11.7%) 30 (8.2%)
  NYHA II 98 (18.9%) 30 (19.5%) 68 (18.7%)
  NYHA III 18 (3.5%) 10 (6.5%) 8 (2.2%)
Diabetes mellitus, n (%) 58 (11.2%) 23 (14.9%) 35 (9.6%) 0.079
Prior stroke or transient ischaemic attack, n (%) 40 (7.7%) 18 (11.7%) 22 (6.0%) 0.028
Coronary Artery Disease, n (%) 66 (12.7%) 27 (17.5%) 39 (10.7%) 0.033
Prior major bleeding 11 (2.1%) 8 (5.2%) 3 (0.8%) 0.004
Paroxysmal AF, n (%) 299 (57.7%) 76 (49.4%) 223 (61.3%) 0.012
Persistent or long- standing persistent AF, n (%) 219 (42.3%) 78 (50.6%) 141 (38.7%) 0.012
Concomitant therapy
  Amiodarone 86 (16.6%) 20 (13.0%) 66 (18.1%) 0.15
  Dronedarone 11 (2.1%) 4 (2.6%) 7 (1.9%) 0.74
  Flecainide 102 (19.7%) 21 (13.6%) 81 (22.3%) 0.024
  Propafenone 14 (2.7%) 4 (2.6%) 10 (2.7%) 1.000
  Sotalol 16 (3.1%) 4 (2.6%) 12 (3.3%) 0.787
  ACE inhibitor or angiotensin receptor blocker 309 (59.7%) 102 (66.2%) 207 (56.9%) 0.047
  Calcium channel blocker 122 (23.6%) 33 (21.4%) 89 (24.5%) 0.459
  Diuretic 179 (34.6%) 62 (40.3%) 117 (32.1%) 0.076
  Statin 186 (35.9%) 51 (33.1%) 135 (37.1%) 0.389
  Beta blocker 364 (70.3%) 110 (71.4%) 254 (69.8%) 0.708
  Digoxin 22 (4.3%) 10 (6.5%) 12 (3.3%) 0.099
Modified EHRA scale at baseline 0.096
  mEHRA I, n (%) 35 (6.8%) 10 (6.5%) 25 (6.9%)
  mEHRA IIa, n (%) 129 (24.9%) 28 (18.2%) 101 (27.7%)
  mEHRA IIb, n (%) 164 (31.7%) 49 (31.8%) 115 (31.6%)
  mEHRA III, n (%) 180 (34.7%) 62 (40.3%) 118 (32.4%)
  mEHRA IV, n (%) 10 (1.9%) 5 (3.2%) 5 (1.4%)
Rhythm at time of ablation
  Sinus rhythm, n (%) 358 (69.1%) 87 (56.5%) 271 (74.5%) <0.001
  Atrial fibrillation, n (%) 144 (27.86%) 63 (40.9%) 81 (22.3%)
  Atrial flutter, n (%) 9 (1.7%) 3 (1.9%) 6 (1.6%)
  Pacing, n (%) 7 (1.4%) 1 (0.6%) 6 (1.6%)
Type of ablation 0.129
  Pulmonary vein isolation 476 (91.9%) 147 (95.5%) 329 (90.4%)
  Pulmonary vein isolation with adjunctive ablation 39 (7.5%) 7 (4.5%) 32 (8.8%)
  Other 3 (0.6%) 0 (0%) 3 (0.8%)
Ablation energy source 0.319
  Radiofrequency, n (%) 323 (62.4%) 100 (64.9%) 223 (61.3%)
  Cryoablation, n (%) 154 (29.7%) 46 (29.9%) 108 (29.7%)
  Other 41 (7.9%) 8 (5.2%) 33 (9.1%)
*Fisher exact test was used when cell size was small, that is, n<5; otherwise Pearson’s χ² was used for categorical and Wilcoxon rank- sum test was used when data is not 
normally distributed; otherwise two- sample t- test used for continuous.
AF, atrial fibrillation; AT, atrial tachycardia; BMI, body mass index; COPD, chronic obstructive pulmonary disease; mEHRA, modified European Heart Rhythm Association.
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likely to have paroxysmal AF (49.4% vs 61.3%, p=0.012) or 
to be in sinus rhythm at the time of ablation (56.5% vs 74.5%, 
p<0.001).
Quality of life according to recurrent AT/AF
At baseline (before ablation), patients with recurrent AT/AF 
had lower SF-12 physical component scores (42 (37, 49) vs 
45 (39,52), p=0.004) and marginally higher MoCA scores 
(28 (26,29) vs 27 (25,29), p=0.002, table 2). After ablation, 
changes in QoL and cognitive function were better in those 
patients without recurrent AT/AF, including the median change 
in SF-12 physical component scores, SF-12 mental component 
scores, EQ- 5D scores, and Karnofsky scores. Figure 1 illus-
trates the change in the SF-12 physical and mental component 
scores according to the presence or absence of recurrent AT/
AF. Figure 2 illustrates the change in Karnofsky Index cate-
gories between those patients with and without recurrent AT/
AF. Notably, in the overall cohort, the proportion with at least 
mild cognitive impairment (MoCA <26) declined from 30.3% 
(n=157) at baseline to 21.8% (n=113) at follow- up.
ANCOVA demonstrated that the mean changes in QoL scores 
were greater among patients without recurrent AT/AF, when 
controlling for baseline measures as shown in table 3. The mean 
differences between those with and without recurrent AF, were 
Table 2 Change in quality of life from baseline to end of study*
All patients (n=518) Recurrent AT/AF (n=154) No recurrent AT/AF (n=364) P value
SF-12 physical component
  Baseline, median (q1, q3) 45 (38 to 52) 42 (37 to 49) 45 (39 to 52) 0.004
  End of study, median (q1, q3) 49 (42 to 54) 45 (38 to 52) 50 (44 to 55) <0.001
  Change, median (q1, q3) 3 (−2 to 8) 1 (−5 to 8) 3 (−1 to 8) 0.026
SF-12 mental component
  Baseline, median (q1, q3) 51 (43 to 58) 51 (45 to 58) 51 (43 to 58) 0.762
  End of study, median (q1, q3) 54 (46 to 59) 52 (42 to 57) 55 (48 to 60) 0.003
  Change, median (q1, q3) 1 (−3 to 8) 0 (−4 to 5) 2 (−3 to 9) 0.004
EQ- 5D scores
  Baseline median (q1, q3) 0.8 (0.7 to 1.0) 0.8 (0.7 to 1.0) 0.8 (0.7 to 1.0) 0.457
  End of study, median (q1, q3) 0.8 (0.7 to 1.0) 0.8 (0.7 to 1.0) 0.9 (0.7 to 1.0) <0.001
  Change, median (q1, q3) 0.0 (0.0 to 0.1) 0.0 (−0.1 to 0.1) 0.0 (0.0 to 0.2) 0.027
Karnofsky scale
  Baseline, median (q1, q3) 90 (80 to 90) 90 (80 to 100) 90 (80 to 90) 0.678
  End of study, median (q1, q3) 100 (90 to 100) 90 (80 to 100) 100 (90 to 100) <0.001
  Change, median (q1, q3) 10 (0 to 10) 0 (0 to 10) 10 (0 to 10) 0.001
MoCA
  Baseline, median (q1, q3) 27 (25 to 29) 28 (26 to 29) 27 (25 to 29) 0.002
  End of study, median (q1, q3) 28 (26 to 29) 28 (27 to 30) 28 (26 to 29) 0.003
  Change, median (q1, q3) 1 (−1 to 2) 1 (−1 to 2) 1 (−1 to 2) 0.628
At least mild cognitive impairment (MoCA <26)
  Baseline, n (%) 157 (30.3%) 33 (21.4%) 124 (34.1%) 0.004
  End of study, n(%) 113 (21.8%) 22 (14.3%) 91 (25%) 0.007
*Fisher exact test was used when cell size was small, that is, n<5; otherwise Pearson’s χ² was used for categorical and Wilcoxon rank- sum test was used when data is not 
normally distributed; otherwise two- sample t- test used for continuous.
AF, atrial fibrillation; AT, atrial tachycardia; MoCA, Montreal Cognitive Assessment.
Figure 1 Change in the SF-12 physical and mental component scores according to the presence or absence of recurrent AT/AF. Shown in each box 
plot are the median changes with 25th and 75th percentiles in the SF-12 physical and mental component scores. The whiskers illustrate the maximum 
and minimum values. AF, atrial fibrillation; AT, atrial tachycardia.
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not statistically significant at the p=0.05 level for any of the 
change in QoL measures except the Karnofsky score (4.9 (9.6) 
vs 7.9 (9.6), p<0.001). We also conducted a sensitivity analysis 
that assessed the proportion of patients with at least a 2.5 point 
increase in the PCS score. The proportion with a 2.5 point 
increase in the PCS was 44.8% (n=69/154) in those with recur-
rent AT/AF vs 52.2% (190/364) in those without recurrent AT/
AF (p for difference after adjusting for baseline PCS=0.002). 
The proportion with a 2.5 point increase in the MCS was 35.7% 
(n=55/154) in those with recurrent AT/AF vs 46.7% (170/364) 
in those without recurrent AT/AF (p for difference after adjusting 
for baseline MCS=0.021).
Associations between functional assessment and patient 
reported outcomes
In order to assess how improvements in functional status 
as measured by physician- determined mEHRA and Karn-
ofsky functional status scores correlate with patient- reported 
outcomes (SF-12 and EQ- 5D scores), we compared changes in 
these metrics. Table 4 details changes in QoL scores according 
to changes in Karnofsky scores. In patients with a decrease or 
no change in the Karnofsky score, the median change in the 
SF-12 physical component was 0.8 (−3.3, 6.5) compared with 
3.3 (−0.4, 9.9) in those with a≥10 point Karnofsky improve-
ment (p=0.002) and 5.4 (1.3, 11.2) in those with a≥20 point 
improvement in the Karnofsky score (p<0.001). Similarly, in 
patients with a decrease or no change in the Karnofsky score, 
the median change in the SF-12 mental component was 0.0 
(−5.6, 5.8) compared with 1.6 (−1.9, 8.8) in those with a≥10 
point Karnofsky improvement (p=0.035), and 2.2 (1.6, 10.0) 
in those with a≥20 point improvement in the Karnofsky score 
(p=0.013). Notably, the median change in the EQ- 5D score 
was not materially different according to changes in the Karn-
ofsky scores despite small but statistically significant improve-
ments. The changes in patient- reported outcomes according to 
changes in mEHRA scores are shown in table 5. Patients with 
>1 class improvement in the mEHRA had greater increase in 
median SF-12 physical component scores at the end of the study 
compared with those with decreased or no change in mEHRA 
classification (p=0.033).
DISCUSSION
Catheter ablation is performed to reduce arrhythmia burden, 
minimise symptoms and to improve QoL. While there are 
several trials that examined the impact of catheter ablation 
on QoL compared with medical therapy, including the recent 
CABANA trial,3 few have examined the impact of recurrent 
AT/AF after ablation on changes in QoL, functional status and 
patient reported outcomes. In our analysis of recurrent AT/
AF after ablation in the AXAFA trial, we found that the raw 
changes in QoL (SF-12 physical and mental scores), EQ- 5D and 
functional (Karnofsky status scores) improved more in patients 
without recurrent AF. After adjustment using ANCOVA, similar 
trends were observed although statistically significant improve-
ment was greater only as measured with the Karnofsky score. 
Finally, we found that cognitive function as assessed by MoCA 
scores improved slightly after ablation regardless of recurrent 
AF.
Catheter ablation is an established therapy for patients with 
medically refractory symptomatic AF. While catheter ablation 
has led to improved cardiovascular outcomes in patients with 
heart failure and left ventricular dysfunction, the primary indi-
cation for ablation is to reduce symptoms and improve QoL. 
The aggregate evidence available from clinical trials demon-
strates improvement in QoL after ablation. In the ThermoCool 
AF trial, patients who underwent ablation experienced signifi-
cant improvement in SF-36 scores (mean+6.9 points for mental, 
Figure 2 Shown in the bar graph are the changes in Karnofsky score 
categories according to the presence or absence of recurrent AT/AF. *P 
value is for the comparison in the change in median Karnofsky scores 
from baseline to follow- up. AF, atrial fibrillation; AT, atrial tachycardia.
Table 3 ANCOVA results comparing baseline and 3- month follow- up 










  Baseline 0.79 (0.22) 0.78 (0.21) 0.79 (0.22)
  End of study 0.83 (0.20) 0.78 (0.21) 0.84 (0.20)
  Change 0.04 (0.21) 0.00 (0.21) 0.05 (0.21) 0.131
SF-12 mental component
  Baseline 49.78 (9.61) 50.07 (9.22) 49.67 (9.78)
  End of study 51.79 (9.24) 49.94 (9.72) 52.58 (8.93)
  Change 2.01 (9.26) −0.12 (9.09) 2.91 (9.19) 0.065
SF-12 physical component
  Baseline 44.31 (9.07) 42.57 (9.07) 45.04 (8.98)
  End of study 47.40 (8.69) 44.43 (9.33) 48.66 (8.09)
  Change 3.10 (8.24) 1.86 (8.93) 3.62 (7.88) 0.238
Karnofsky
  Baseline 86.3 (10.2) 85.8 (11.2) 86.5 (9.8)
  End of study 93.2 (9.7) 90.6 (11.4) 94.3 (8.6)
  Change 7.0 (9.7) 4.9 (9.6) 7.9 (9.6) <0.001
MoCA
  Baseline 26.6 (2.8) 27.1 (2.5) 26.3 (2.9)
  End of study 27.2 (2.8) 27.7 (2.6) 27.0 (2.9)
  Change 0.6 (2.5) 0.6 (2.3) 0.7 (2.6) 0.924
The p value in this table corresponds to the effect of recurrent AT/AF group in an 
ANCOVA model with change from baseline as the dependent variable, and baseline 
values and recurrent AT/AF group as covariates.
AF, atrial fibrillation; ANCOVA, analysis of covariance; AT, atrial tachycardia; MoCA, 
Montreal Cognitive Assessment; QoL, quality of life.
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+6.6 for physical) at 9 months of follow- up.2 Similarly, in the 
Catheter Ablation compared with optimised Pharmacological 
Therapy for Atrial Fibrillation (CAPTAF) trial, in which QoL 
was the primary endpoint, catheter ablation led to superior QoL 
compared with medical therapy at 12 months of follow- up.4 
Most recently, the CABANA trial demonstrated that catheter 
ablation led to significant improvements in QoL that were main-
tained at 5 years after ablation when compared with medical 
therapy.3 Despite randomised trials comparing QoL with abla-
tion versus medical therapy, few data are available comparing 
QoL, functional status and patient- reported outcomes in patients 
according to recurrence of atrial arrhythmias after ablation.
Consistent with our hypothesis, we observed that improve-
ment in functional status was greater in those patients without 
recurrent AT/AF, as reflected by highly significant improve-
ment in Karnofsky scores. However, we did not identify greater 
improvements in QoL in those without recurrent AT/AF. While 
the median changes in the SF-12 physical and mental scores were 
more favourable in patients without recurrent AT/AF, ANCOVA 
did not identify statistically significant greater improvement 
SF-12 physical (p=0.238) or mental scores (p=0.065) in those 
without recurrent AT/AF compared with patients with recur-
rent AT/AF. Finally, while the change in MoCA scores was not 
different between those with and without recurrent AT/AF after 
the 3- month follow- up, the proportion of the overall cohort 
with mild or greater cognitive impairment decreased from 30% 
to 22%. This cognitive improvement could also be related to 
an increased familiarity of the test by patients. Nonetheless, this 
finding is reassuring, particularly in light of findings of asymp-
tomatic cerebral emboli in patients undergoing catheter abla-
tion.6 7
Patient- reported outcomes are defined as any report of the 
status of a patient’s health that comes directly from the patient, 
without interpretation of the patient’s response by a clinician 










Change in SF-12 physical component score compared with baseline (Δ PCS)
  Mean (SD) 1.5 (8.2) 4.5 (8.0) 6.5 (7.9)
  Median (25th, 75th) 0.8 (−3.3 to 6.5) 3.3 (−0.4 to 9.9) 5.4 (1.3 to 11.2)
  Min, Max −19 to 30 −17 to 26 −16 to 26
  P value (compared with decrease or no change) 0.002 <0.001
Change in SF-12 mental component score compared with baseline (Δ MCS)
  Mean (SD) 0.3 (9.4) 3.5 (8.9) 4.4 (9.3)
  Median (25th, 75th) 0.0 (−5.6 to 5.8) 1.6 (−1.9 to 8.8) 2.2 (−1.6 to 10.0)
  Min, Max −29 to 26 −22 to 44 −21 to 44
  P value (compared with decrease or no change) 0.035 0.013
Change in EQ- 5D score compared with baseline (Δ EQ- 5D)
  Mean (SD) 0.0 (0.2) 0.1 (0.2) 0.1 (0.2)
  Median (25th, 75th) 0.0 (−0.1 to 0.1) 0.0 (0.0 to 0.2) 0.0 (0.0 to 0.2)
  Min, Max −1 to 1 −1 to 1 −1 to 1
  P value (compared with decrease or no change) 0.040 0.001
The patients with ≥20 point improvement in the Karnofsky score (n=107) are also included in the group of patients with ≥10 point improvement (n=267). Unadjusted p values are from median 
comparison with ‘Decrease or No Change in Karnofsky Score’ group.




Any improvement in 
mEHRA
(n=437)






Change in SF-12 physical component score compared with baseline (Δ PCS)
  Mean (SD) 0.6 (8.3) 3.6 (8.2) 1.7 (7.7) 4.5 (8.2)
  Median (25th, 75th) 0.9 (−5.8 to 5.8) 2.7 (−1.4 to 8.8) 0.6 (−2.2 to 5.5) 3.8 (−1.0 to 9.6)
  Min, Max −19 to 26 −18 to 18 −19 to 26 −18 to 30
  P value (compared with decrease or no change) 0.277 0.851 0.033
Change in SF-12 mental component score compared with baseline (Δ MCS)
  Mean (SD) 0.9 (8.9) 2.2 (9.3) 1.7 (8.0) 2.5 (9.9)
  Median (25th, 75th) 0.0 (−3.3 to 5.0) 1.4 (−3.1 to 8.3) 1.6 (−2.4 to 7.3) 1.2 (−3.2 to 8.9)
  Min, Max −29 to 27 −22 to 44 −22 to 22 −24 to 44
  P value (compared with decrease or no change) 0.116 0.08 0.259
Change in EQ- 5D score compared with baseline (Δ EQ- 5D)
  Mean (SD) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2)
  Median (25th, 75th) 0.0 (−0.1 to 0.1) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.2)
  Min, Max −1 to 1 −1 to 1 0 to 1 −1 to 1
  P value (compared with decrease or no change) 0.343 0.879 0.179
*Unadjusted p values from median comparisons with 'Decrease or No Change in mEHRA' group.
mEHRA, modified European Heart Rhythm Association.
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or anyone else. Patient- reported outcomes have been increas-
ingly emphasised by regulatory bodies, including the Food and 
Drug Administration. AXAFA included several patient- reported 
outcomes including the physical and mental components of the 
SF-12 and EQ- 5D. There are few data regarding how clinician- 
derived and patient- reported assessments of improvement in 
functional status and QoL relate to one another. Results from 
the ORBIT registry suggest that changes in patient- reported QoL 
with the AFEQT score do correlate with the EHRA scores.17 
In AXAFA, we found that improvements to Karnofsky score 
appeared to be reflected by improvements in patient- reported 
outcomes including the SF-12 physical and mental components.
Limitations
There are several limitations that should be kept in mind when 
considering these data. This is a secondary analysis of data from 
a randomised controlled trial and QoL data were not available 
for all patients. While the hypothesis tested in our analysis was 
whether changes in QoL after ablation differ according to the 
presence or absence of recurrent AT/AF, we did not have a 
comparator group who did not undergo ablation. Additionally, 
the changes in QoL were analysed at 3 months and therefore 
reflect intermediate term outcomes after AF ablation. Further-
more, despite of using different test versions, a learning effect by 
serial testing has to be taken into account.
CONCLUSION
AF ablation resulted in very good functional status in this large 
cohort of patients with stroke risk factors. Patients without 
recurrent AT/AF experience greater improvement in functional 
status after AF ablation. Future studies should examine how 
changes in QoL, cognition and functional status vary according 
to arrhythmia recurrence in long- term follow- up.
Key messages
What is already known on this subject?
 ► Catheter ablation of atrial fibrillation (AF) improves quality 
of life.
What might this study add?
 ► This study examines how quality of life changes according to 
outcomes after AF ablation.
How might this impact on clinical practice?
 ► Patients without recurrent atrial tachycardia/AF experience 
greater improvement in functional status after AF ablation. 
Assessing patient- reported outcomes after ablation is 
important to help guide treatment and improve outcomes.
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